SPEEDEL Reports on Data Published at Hypertension 2008 Mediacal Congress
Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presente…
Speedel Holding Ltd. (SWX: SPPN) today announced that data for two of its developmental product candidates were presente…
Speedel Holding Ltd. (SWX: SPPN) highlighted today that Novartis is to expand the clinical trial programme with SPP100 (…
Data from the AVOID study published in this week's New England Journal of Medicine demonstrate that the first-in-class d…
Speedel (SWX: SPPN) today welcomed promising results from the latest SPP100 (Tekturna/Rasilez[1]) surrogate marker clin…
Speedel Holding Ltd (SWX: SPPN) today announced consolidated financial results for the year ending 31 December 2007.…
Speedel Holding Ltd (SWX: SPPN) today announced that it is delighted by the FDA approval of a second product containing…
Speedel Holding Ltd (SWX: SPPN) today welcomes the promising results of SPP100 (Tekturna/Rasilez[1]) in the AVOID[2] Ph…
Speedel Holding Ltd (SWX: SPPN), today unveiled SPP676 as a new renin inhibitor with the announcement that the promising…
Speedel (SWX: SPPN) today welcomed the announcement that Speedel and Novartis have won the overall Gold Award in the sev…
Speedel (SWX: SPPN) today welcomed the promising results of SPP100 (Tekturna/Rasilez[1]) in a Phase II clinical trial w…